Skip to content

Multicenter, National, Observational, Prospective, Real-life Study Evaluating the Performance of 2% Aqueous Eosin in Children With Diaper Rash

Real-life Study Evaluating the Performance of 2% Aqueous Eosin in Children With Diaper Rash

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05599763
Acronym
EA2
Enrollment
67
Registered
2022-10-31
Start date
2022-11-04
Completion date
2023-04-19
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaper Rash

Brief summary

This study is being conducted to provide updated clinical data on safety and performance (demonstrated previously for CE marking under the Medical Devices Directive) Cooper Aqueous Eosin 2%. This is an observational study conducted under real-life conditions and as part of post-marketing surveillance activity for a device that has been on the market for a long time and a well-established technology, in accordance with the Medical Devices Regulations 2017 /745 (MDR) and MDCG 2020-6 guidelines. The study will be a multicenter, national, observational, prospective study, with a 7-day follow-up (+/- 2 day). 60 patients are scheduled.

Interventions

None listed

Sponsors

Cooperation Pharmaceutique Francaise
Lead SponsorINDUSTRY
Clin-Experts
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 24 Months
Healthy volunteers
No

Inclusion criteria

* Children under 24 months * With diaper rash for which a prescription for 2% aqueous eosin in a 50 ml vial is made * SSDDS score \>= 3/6 * Not requiring hospitalization * Written consent of one of the parents * Affiliated with social security * Acceptance of one of the parents to participate in a visit on day 7 in the office or, in case of impossibility, with video/internet consultation or with consultation by phone and sending a photo in this case by the parent(s).

Exclusion criteria

* Antibiotic therapy in progress or prescribed on day 0, or other local therapeutic topicals prescribed on day 0 * Children with wounds or likely to be allergic to 2% aqueous eosin or to one of the components of 2% aqueous eosin. * Ongoing diarrhoea (change in the consistency of stools (loose or watery) and / or an increase in the number (≥ 3 stools / day).

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with an SSDDS score < 3/6 or an improvement of at least 2 pointsat day 7 +-2 daysThe SSDDS (Scoring System for Diaper Dermatitis Scale) score is a severity score : the sum of the scores for four areas: severity of erythema and irritation (score from 0 to 3), extension (0 to 1), presence of papules or pustules (0 to 1) and open skin (0 to 1). The possible scores range from 0 (fair skin) to 6 (extensive diaper rash including intense erythema, papules or pustules and open skin with lesion of the dermis).

Secondary

MeasureTime frameDescription
Percentage of patients completely curedat day 7 +/-2 days
Healing time according to parentup to 9 days
Change of the SSDDS score between day 0 and day 7at day 7 +/-2 daysThe SSDDS (Scoring System for Diaper Dermatitis Scale) score is a severity score : the sum of the scores for four areas: severity of erythema and irritation (score from 0 to 3), extension (0 to 1), presence of papules or pustules (0 to 1) and open skin (0 to 1). The possible scores range from 0 (fair skin) to 6 (extensive diaper rash including intense erythema, papules or pustules and open skin with lesion of the dermis).
Change in associated signs between day 0 and day 7at day 7 +/-2 days
Assessment of toleranceat day 7 +/-2 daysTolerance is measured by adverse events reported
Assessment of complianceat day 7 +/-2 daysAccording to the judgment of the investigator

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFrédéric HUET

CHU DIJON

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026